Gland Pharma IPO allotment: Here’s how to check share allotment status

• The basis of allotment for Gland Pharma IPO will be announced on November 17, and the shares will hit the bourses on November 20.
• The issue received bids for 62 million shares against the offer size of 30 million shares
• Here’s how to check Gland Pharma IPO allotment status on NSE, BSE, and the registrar website.
• Check out the latest news and updates on Business Insider.

After receiving a tepid response from investors, the ₹6,480 crore IPO of Gland Pharma closed on Wednesday. The issue was oversubscribed by 2.05 times — which is lower compared to some of the recently concluded IPO like Mazagon Dock Shipbuilders, Chemcon Speciality Chemicals and others.

The issue received bids for 62 million shares against the offer size of 30 million shares.


The basis of allotment for Gland Pharma IPO will be announced on November 17, and the shares will hit the bourses on November 20.

Here’s how to check Gland Pharma IPO allotment status:

If you subscribed for the Gland Pharma IPO, you could check your allotment status by following these simple steps:

To check on the stock-exchange website:

• To check the Gland Pharma IPO allotment status, go to the BSE website or NSE website here.
• On BSE, Select ‘Equity’ and then from the dropdown, select ‘ Gland Pharma’.
• Now, enter your application number and PAN.
• Click on ‘Search’.

Please note the details will only be available once the shares are allotted.

You can also visit the Registrar website (Linkintime) to check your application status.

• Visit the registrar’s website here.
• Click on ‘Select company’ and click on ‘ Gland Pharma-IPO’. It will only appear post allotment on November 17.
• Once the company is selected, you will have to enter either your PAN detail, the application number, or client ID.
• Enter the captcha and click ‘submit’.

Once you hit ‘submit’ the status of your application will appear on the screen. Please ensure the details that you provide are correct. It will show the number of shares that you subscribed to and the number of shares that have been allotted to you.

SEE ALSO: JPMorgan’s quant chief shares 5 trade recommendations following Pfizer’s vaccine ‘game-changer’

How to invest in tech stocks, a risky but fast-rising segment of the market